Skip to main content

Table 1 Demographic characteristics at baseline in the total vaccinated cohorts

From: A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

  TIV QIV
N = 120 N = 112
18–60 years >60 years 18–60 years >60 years
n = 50 n = 70 n = 56 n = 56
Mean age, years (SD; median; range) 34.8 66.6 40.9 68.6
(13.72; 28.0; 19.0–59.0) (4.73; 65.0; 61.0–81.0) (13.33; 39.5; 22.0–60.0) (4.72; 67.5; 61.0–82.0)
Male, n (%) 17 (34.0) 31 (44.3) 22 (39.3) 26 (46.4)
Female, n (%) 33 (66.0) 39 (55.7) 34 (60.7) 30 (53.6)
Ethnic origin, n (%)     
White Caucasian/European heritage 47 (94.0) 69 (98.6) 54 (96.4) 56 (100)
Other 3 (6.0) 1 (1.4) 2 (3.6) 0
Seasonal influenza in at least 1 season from previous 3 seasons 20 (40.0) 44 (62.9) 54 (96.4) 54 (96.4)
AS03-adjuvanted pandemic influenza vaccine in the previous (2010–2009) season 26 (52.0) 33 (47.1) n/a n/a
  1. TIV, inactivated trivalent influenza vaccine; QIV, inactivated quadrivalent influenza vaccine; SD, standard deviation.